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Abbreviations: 
 
AIH autoimmune hepatitis 
 
anti-LKM1 antibodies to liver-kidney microsome type 1 
 
ANA  antinuclear antibodies  
 
HLAs  human leukocyte antigens  
 
IgG  immunoglobulin G  
GSTT1 glutathione-S-transferase T1 
LT  liver transplantation  
PBC  primary biliary cholangitis  
rAIH  recurrent AIH  
SMA  smooth muscle antibodies  
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ABSTRACT 
Clinical indications for liver transplantation (LT) in patients with autoimmune 
hepatitis (AIH) are identical to those of patients with other chronic liver diseases that end in 
acute or semi-acute liver failure, decompensated cirrhosis, or hepatocellular carcinoma. 
Recurrent disease after LT has been reported in 10-50% of patients with AIH, and the 
frequency of detection is influenced in part by the use of protocol or clinically indicated liver 
biopsy. De novo AIH connotes the development of AIH in patients transplanted for liver 
diseases other than AIH, and it has been reported in 5-10% of pediatric and 1-2% of adult 
recipients. Recurrent disease can negatively impact on graft and patient survival, and re-
transplantation has been required in 8-23%. De novo AIH is within the spectrum of graft 
dysfunction that includes plasma cell-rich rejection, and it can also progress to cirrhosis and 
graft failure. Treatment for recurrent or de novo disease is based on the conventional 
regimens for AIH, and corticosteroid therapy alone or combined with azathioprine is 
standard. Better control of disease activity prior to LT has been associated with less 
recurrence, and maintenance corticosteroid treatment after LT can reduce its frequency. 
Conclusions. Recurrent AIH is far more frequent than de novo AIH. Both may have negative 
impacts on graft and patient survival, and early detection and treatment are key objectives. 
Future investigations must codify the diagnostic criteria for each graft dysfunction, seek 
diagnostic biomarkers, and evaluate treatments that improve outcomes without increasing the 
risk of pre- and post-LT infections. 
 
INTRODUCTION 
Autoimmune hepatitis (AIH) is a complex and rare disease, characterized by 
hypergammaglobulinaemia, autoantibodies, certain human leukocyte antigens (HLAs), 
interface hepatitis on histological examination, and in most cases, an appropriate response to 
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immunosuppression (1, 2).  Its clinical, laboratory, immunological and histological features 
are diverse, and the diagnosis should be considered in all patients with acute or chronic liver 
disease, particularly if hypergammaglobulinemia and other autoimmune diseases are present. 
Clinical indications for liver transplantation (LT) in patients with AIH are identical to 
patients with other chronic liver diseases that end in acute or semi-acute liver failure, 
decompensated cirrhosis, or hepatocellular carcinoma (3). Liver transplantation has been a 
lifesaving intervention for decompensated AIH, and 1- and 5-year survivals are 
approximately 90% and 70%, respectively (4). Recurrent AIH (rAIH) is a cause of allograft 
dysfunction, reduced graft and patient survival, and need for re-transplantation. Its prevalence 
increases with time after LT, and prompt diagnosis and intervention are essential in 
preventing or limiting its consequences. 
The prevalence of rAIH ranges from 17-42% (5-7), depending in part on the use of 
protocol liver biopsy assessments or a clinically indicated liver biopsy strategy.  Quality of 
life as well as graft and patient survival may be adversely affected by rAIH regardless of the 
immunosuppression regimens employed (8, 9). Diagnosis is challenged by the variable 
criteria used to define disease recurrence, the lack of specific biomarkers for rAIH, and the 
difficulty in distinguishing rAIH on histological examination from alloreactivity. Acute and 
late onset T-cell mediated rejection (occurring after 90 days) develops more frequently in 
recipients with AIH than recipients with other liver diseases, and this may confound the 
clinical and histological diagnosis of rAIH (3, 10).  
De novo AIH develops in recipients transplanted for other reasons than AIH. This 
condition was initially described in children after LT, predominantly in patients with biliary 
atresia (11). Subsequently, de novo AIH has been recognized in adults transplanted for other 
etiologies, and one series reported a higher prevalence in recipients with primary biliary 
cholangitis (PBC) (12). The incidence of de novo AIH is unknown as the disease lacks 
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codified diagnostic criteria. Furthermore, the outcome of de novo AIH is unclear as studies 
assessing its impact on graft or patient survival are small. Recipients of female grafts or older 
donors have a higher prevalence of de novo AIH, suggesting that the risk associated with de 
novo AIH may be dictated by the allograft itself (12). 
Published literature uses highly variable diagnostic criteria, different regimens of 
maintenance immunosuppression and relies heavily on biopsy features, none of which are 
specific for AIH. Thus, in the absence of both validated diagnostic biomarkers for AIH or 
validated diagnostic criteria for either rAIH or de novo AIH post-LT, we have critically 
evaluated the published literature in this review. We describe the frequency and risk factors 
associated with the development of recurrent and de novo AIH following LT. We also discuss 
the clinical significance and management strategies for each of these graft dysfunctions. 
 
Autoimmune Hepatitis 
AIH is a chronic inflammation of the liver associated with interface hepatitis, 
increased serum immunoglobulin G (IgG) level, and autoantibodies (1, 13, 14). The 
pathogenesis is not completely understood, but AIH is probably triggered by environmental 
elements in a genetically susceptible individual. Patients develop loss of self-tolerance, and 
dysregulated T-cell mediated immune responses can result in long-term hepatic 
inflammation, injury, and fibrosis (15).  
Two types of AIH (type 1 and type 2) are recognized based on serological markers (2, 
16). Type 1 AIH is characterized by the presence of antinuclear antibodies (ANA), smooth 
muscle antibodies (SMA) or both, and it constitutes more than 80% of cases. Type 2 AIH is 
characterized by antibodies to liver-kidney microsome type 1 (anti-LKM1) and/or antibodies 
to liver cytosol antigen type 1 (anti-LC1).  Most patients with type 2 AIH are children (14).  
Type 3 AIH was described after the finding of antibodies against soluble liver antigens (anti-
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SLA) (17). These antibodies were subsequently found to have identical reactivities to the 
previously described antibodies against liver pancreas (anti-LP) (18), and the early 
designation of these antibodies as anti-SLA/LP indicated this identity (19). The 
subclassification of type 3 AIH is still controversial as the difference in clinical behaviour 
between type 1 and type 3 AIH is not significant (2).    
 
Liver Transplantation for AIH 
AIH accounts for approximately 6% of all pediatric and adult LTs in North America 
(16). Patients with AIH that need a LT can present with either acute liver failure with poor 
response to treatment, decompensated cirrhosis at diagnosis or after prolonged 
immunosuppression therapy, or less frequently, with hepatocellular carcinoma (20, 21).  
Factors predictive of treatment failure and disease progression are young age at diagnosis, 
acute presentation, high serum bilirubin level, MELD score >12 at diagnosis, and the HLA 
DRB1*03 phenotype (20). It has been reported that lack of response to standard 
immunosuppressive regimens is predictive of LT, especially when there is less than 50% 
improvement of serum aminotransferase levels after 6 months of treatment (22). In general, 
outcomes after LT for patients with AIH are satisfactory, with a 5- and 10-year overall 
survival of 86% and 73%, respectively (Table 1) (23). 
 
Possible Pathogenic Pathways for rAIH and De novo AIH 
The pathogenic mechanisms for AIH before LT are probably similar to those that 
promote recurrent and de novo AIH, but the introduction of a donor allograft with different 
antigen-presenting and immune-reactive cells can alter the recipient’s immune response. 
Autoimmunity infers that there is a loss of tolerance for self-antigens and that an immune 
response is mounted against host antigens presented by host-derived antigen-presenting cells 
A
cc
ep
te
d 
A
rt
ic
le
 
 
 
This article is protected by copyright. All rights reserved. 
(24). After LT, autoantigens may not only be presented by self-derived class I and II HLA 
and recognized by self-derived CD4+ and CD8+ T cells, but they may also be presented by 
donor-derived HLA. Recipient memory T cells that should be restricted to self-derived HLA 
may also react with donor-derived HLA, and rAIH may be a consequence. In de novo AIH, 
there has been no preceding autoimmune reaction in the recipient, and the donor liver may 
introduce new antigens and immune-reactive cells that institute a weakening of immune 
tolerance (25). 
A similar mechanism has been observed in patients with hepatitis C virus (HCV) 
infection following LT. HCV-specific CD8+ T cells have recognized viral antigen presented 
by HLA-A2 in the allograft in a HLA-A2 negative recipient, i.e. by non-self HLA on donor 
hepatocytes (26). The genetic susceptibility provided by HLA DRB1*0301 and DRB1*0401 
alleles has been associated with rAIH (27), but the role of the HLA phenotype in de novo 
AIH is not certain. It is speculated that presentation of antigens by the donor or recipient 
antigen-presenting cells activates the memory T cells of the recipient, which in turn enables a 
self-directed immune attack (28) (Figure 1). 
Hidden or sequestered epitopes may also contribute to immune-mediated graft 
damage as inflammation and tissue injury can trigger reactive T cells that unmask neo-
antigens (29). Furthermore, reactivity to an immunodominant epitope may expand to 
neighboring and remote regions of the epitope in association with the disease duration. The 
expansion of reactivity to sequence homologies within the same antigen constitutes an 
epitope spread, and it supports molecular mimicry as a possible mechanism of autoreactivity 
after LT (30). Viral infection has been proposed as a trigger for rAIH and de novo AIH, but 
this finding requires corroboration (31).  
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Most cases of rAIH and de novo AIH occur in patients receiving calcineurin 
inhibitors (CNI). CNI obstruct T cell activation through T cell receptors, where interleukin-2 
(IL-2) is required for the survival and proliferation of regulatory T cells (Treg). As CNI 
decrease the production of IL-2, Treg function may be altered. In animal models, 
autoimmune disease caused by CNI has been related to impairment of T cell-regulated 
suppressor function and subsequent development and activation of auto-reactive T cells (32, 
33). 
The triggering antigens in post-LT AIH may differ, and the alloreactive responses 
may be modified by ongoing antirejection treatment. Patients developing rAIH have already 
demonstrated a defect in immune tolerance for auto-antigens, and the factors that 
predisposed individuals to develop the original disease are unlikely to change after LT. In 
patients with de novo AIH, exposure of the recipient to new antigens and immune cells from 
the graft, re-population of the donor liver with antigen-presenting cells from the recipient, 
sequestration and re-activation of antigen-sensitized lymphocytes within the recipient, and 
drug-induced alterations in immune regulatory cells could promote autoreactivity (Figure 1) 
(34). 
 
Recurrent Autoimmune Hepatitis 
Frequency of rAIH 
Establishing an accurate estimate of frequency for rAIH has been difficult. Different 
groups have employed diverse diagnostic criteria and strategies for sampling liver tissue (5). 
The diagnostic criteria for rAIH have not been codified by the International Autoimmune 
Hepatitis Group (IAIHG) or other liver societies (35), and the diagnostic scoring systems for 
AIH have not been validated for rAIH (36). Furthermore, the histological features of rAIH 
may be atypical of classical AIH, and the manifestations of focal lymphocytic cholangitis and 
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perivenular hepatocyte necrosis of the terminal hepatic venules may suggest T-cell mediated 
rejection (37, 38). The diagnosis of rAIH cannot be made by histological examination alone, 
and the required clinical and laboratory features that support the diagnosis lack diagnostic 
specificity. Consequently, it is not surprising that the reported frequency of rAIH ranges from 
10-68% depending on the diagnostic criteria that are applied and on the observation interval 
after LT. The frequency of rAIH increases with time after transplantation, and rAIH has been 
found in 8-12% after 1 year (39, 40) and 36-68% after 5 years (5, 39). 
Case series have been too small to demonstrate an increased risk of graft loss or 
mortality in recipients with rAIH compared to recipients with other liver diseases.  
Nevertheless, progression to cirrhosis, graft failure, and re-transplantation have occurred with 
rAIH (41, 42), and these possible outcomes, estimated at 13-23% in small series, have 
justified efforts for early diagnosis and effective treatment.  
Diagnostic Features of rAIH (Table 2) 
The diagnostic criteria for rAIH are the same that have been promulgated for the 
original disease (16, 35). Post-transplant variations in the clinical phenotype of rAIH can 
complicate its recognition, and some features may be less pronounced, absent, or otherwise 
atypical in part because of concurrent antirejection therapy and the duration or stage of the 
disease before its detection (43-45). Patients may be asymptomatic, and the diagnosis 
considered only because surveillance tests reveal serum aminotransferase abnormalities and 
the need for liver tissue examination. Other patients may have normal liver tests but abnormal 
protocol-directed liver tissue examinations (43, 44). An acute severe hepatitis is a rare 
possibility because of concurrent immunosuppressive therapy. 
Interface hepatitis is the hallmark of rAIH with or without plasma cell infiltration (37, 
46). Primary histological alterations include acute lobular hepatitis with focal hepatocyte 
necrosis, acidophil bodies with lymphoplasmacytic cells, and pseudo-rosetting of hepatocytes 
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(37, 46). Delayed histological alterations are lymphoplasmacytic portal and lobular infiltrates 
and interface hepatitis (37). Confluent and bridging necrosis with lymphoplasmacytic 
infiltration connote severe inflammatory activity. 
All causes of allograft dysfunction in patients transplanted for AIH must be 
considered as rAIH, and the diagnosis requires the exclusion of other considerations, 
especially allograft rejection. Drug hepatotoxicity, de novo steatohepatitis, and viral hepatitis, 
including hepatitis E, should be excluded. 
The presence of focal lymphocytic cholangitis and perivenular hepatocyte necrosis of 
the terminal hepatic venules support the possibility of T-cell mediated rejection (37). Main 
histological aspects of rAIH are prominent lymphocytic interface activity, pseudo-rosetting 
of hepatocytes, and perivenular lymphoplasmacytic inflammation (37). 
Risk Factors for rAIH (Table 3) 
The risk factors for rAIH after LT are poorly understood. Inflammatory activity prior 
to LT has been associated with rAIH (5). Increased serum aminotransferase and IgG levels 
prior to LT as well as the presence of lymphocytic or lymphoplasmacytic infiltration with 
moderate to severe inflammatory activity in the explant have been associated with a high risk 
of rAIH (5). Furthermore, HLA DRB1*03 has been associated with severe AIH before LT 
and rAIH after LT (27, 47). These results suggest that active disease before LT directly 
impacts on the development of rAIH and that recurrence may simply be a continuum of the 
original disease (34, 48). Future studies must evaluate if more powerful immunosuppression 
prior to LT can reduce the occurrence of rAIH. They must also determine if the benefit can 
counterbalance the increased risk of side effects from more intense pre-operative therapy. 
Other risk factors that have been proposed but remain unestablished are HLA 
mismatching between donor and recipient (47), antecedent episodes of rejection (49), 
corticosteroid withdrawal and inadequate immunosuppression (50), and a paradoxical 
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stimulatory immune response induced by the calcineurin inhibitor (51).  When HLA 
DRB1*03 mismatching was evaluated in one case series, the frequency of mismatching did 
not have any impact on the frequency of rAIH (52). In contrast, HLA mismatching at the DR 
locus was associated with an increased frequency of rAIH in the National Institutes of Health 
Liver Transplantation Database. HLA mismatching, however, did not predict patient or graft 
survival (53), and no changes in current management guidelines were recommended. 
The development of T-cell mediated rejection did not influence the frequency of 
rAIH (3); and experiences evaluating the association of low dose maintenance 
immunosuppression and corticosteroid withdrawal with the risk of rAIH (40, 52) have been 
discrepant (39, 54). Firm conclusions about the impact of corticosteroid withdrawal in AIH 
post-LT cannot be made from these uncontrolled studies, but the maintenance of long-term, 
low dose corticosteroid therapy after LT has generally been well tolerated and mitigates 
concern about rAIH. This approach has been supported by the findings in a British study that 
has demonstrated the safety of protracted corticosteroid treatment (prednisolone, 5-10 mg 
daily) for AIH after LT and a low incidence of rAIH (23). Furthermore, the frequency of 
sepsis and osteoporosis was comparable to that encountered in the general recipient 
population.  
 
Outcomes and Treatment of rAIH 
Treatment of rAIH is empiric and depends on the presentation, which can be variable. 
When patients present with asymptomatic disease and minimal changes in liver tests or 
histological features, minor adjustments that increase the immunosuppression may be 
sufficient to suppress recurrent disease (40, 55). When patients present with severe rAIH, 
starting prednisone or prednisolone, 30 mg daily, in combination with azathioprine, 1-2 
mg/kg daily, is usually effective in inducing laboratory improvement.  The dose of 
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prednisone or prednisolone can then be reduced to 5-10 mg daily within 4 to 8 weeks and 
maintained thereafter (56). Failure of rAIH to respond to the combination of corticosteroids 
and azathioprine justifies consideration of other strategies, such as an alternative calcineurin 
inhibitor, mycophenolate mofetil (MMF), or rapamycin (57, 58). 
 
Re-transplantation may be necessary for patients with rAIH who present with liver 
failure and graft loss. Re-transplantation has been reported mainly in children and young 
adults. In one North American center, 60% of children with rAIH developed cirrhosis, and 
evidence for rAIH was observed in all patients that required re-transplantation (41). In adults, 
graft failure has been reported in 13% to 50% with rAIH (42, 52). These reports suggest that 
the development of cirrhosis with subsequent graft loss occurs despite intensive 
immunosuppressive therapy in some patients with rAIH.  rAIH has been associated with a 
higher risk of graft loss and an increased risk of death from liver failure compared to other 
liver diseases 1-year post-LT (59). 
 
De Novo Autoimmune Hepatitis 
Frequency of De novo AIH 
De novo AIH is a clinical entity resembling AIH that develops in recipients 
transplanted for liver diseases other than AIH. It was originally described in children after 
LT, predominantly in those with biliary atresia (11), and subsequently found in a higher 
prevalence of LT recipients with PBC (12). The first description of de novo AIH in children 
in 1998 involved seven of 180 children who were followed for at least 5 years after LT. 
These patients presented with histological features of AIH, hypergammaglobulinemia and 
high titers of ANA, and/or SMA and/or anti-LKM1. Six of the seven patients responded to 
therapy with corticosteroids and azathioprine (11). De novo AIH was subsequently described 
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in another population of children in 2001 (60), in adults transplanted for PBC in 1999-2010 
(61, 62), in adults transplanted for drug-induced liver failure, alcoholic cirrhosis, primary 
sclerosing cholangitis (PSC), PBC, cryptogenic cirrhosis, and hepatitis C-related cirrhosis in 
2001 (63), and in 4 of 9 patients transplanted for chronic hepatitis C who had been treated 
with pegylated interferon (Peg-IFN) and ribavirin (RBV) for recurrent chronic hepatitis C in 
2007 (64). 
The term, de novo AIH, has been challenged, and the Banff working group on liver 
allograft pathology has suggested that this term be abandoned. The term, “plasma-cell rich 
rejection” has been recommended as a substitute since the histological features of 
lymphocytic cholangitis, central perivenulitis, and T cell-mediated rejection are atypical for 
AIH (65). Countering this proposal are observations that less potent immunosuppression 
appears protective against de novo AIH; patients with AIH can manifest these same atypical 
features outside the context of LT; and the majority of patients with de novo AIH have high 
serum levels of IgG and characteristic autoantibodies (3, 12, 66). Further studies will be 
required to determine if this form of graft dysfunction constitutes an autoimmune (de novo 
AIH) or an alloimmune (plasma-cell rich rejection) reaction (38, 67). 
The frequency of de novo AIH has been estimated at 5-10% of pediatric recipients 
and 1-2% in adult recipients.  In one study, de novo AIH was diagnosed in 17 of 576 patients 
(3%), and the overall incidence was 4.0 cases per 1000 patient-years (12) (Table 4). 
Diagnostic Features of De novo AIH (Table 2) 
The clinical manifestations of de novo AIH are similar to those of rAIH and classical 
AIH. Most patients have hypergammaglobulinemia, increased serum IgG levels, and ANA, 
SMA, or both ANA and SMA. Children with de novo AIH may have anti-LKM1, antibodies 
to gastric parietal cells, or anti-LC (68). The diagnosis has been made in the absence of 
autoantibodies and increased serum IgG level in some patients by depending on the 
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histological findings and response to immunosuppressive therapy (69, 70). An atypical anti-
liver/kidney cytosolic antibody that reacts to rat hepatocyte cytoplasm, mainly in the 
centrilobular area, has been described in adults with de novo AIH, and the target antigen is 
glutathione-S-transferase T1 (GSTT1) (31, 71).   
Portal and periportal (interface) hepatitis with lymphocytes and plasma cells are the 
main histological features of de novo AIH (11). Perivenular cell necrosis (11), lobular 
hepatitis (31), portal fibrosis (60, 68), zonal necrosis (61), and centrilobular necrosis (62) 
have also been described. 
Risk Factors for De Novo AIH (Table 3) 
Recipients of female grafts or older donors have a higher prevalence of de novo AIH, 
suggesting that the risk for de novo disease is harbored within the allograft (12). De novo 
AIH has also been related to atypical serum autoantibodies, the majority of which are 
directed against GSTT1 (anti-GSTT1) (72, 73). Indeed, the mismatching of donor and 
recipient for the GSTT1 genotype has been proposed as essential for the appearance of anti-
GSTT1 and the development of de novo AIH (Table 3). 
In one study of 419 adult recipients with donor/recipient GSTT1 mismatching, 29 
patients (7%) had anti-GSTT1, and 20 of 27 assessable patients (74%) developed de novo 
AIH over a median follow-up time of 26 months. The probability of de novo AIH was 60% at 
36 months. Multivariate analysis has identified male donor [hazard ratio (HR), 3.3; 95% CI, 
1.18-9.26; P=0.02], nonalcoholic etiology (HR, 4.67; 95% CI, 1.64-13.3; p=0.002), and high 
anti-GSTT1 titer (HR, 2.98; 95% CI, 1.04-8.57; p=0.04) as independent predictors of de novo 
AIH (73). 
Interestingly, the administration of granulocyte colony-stimulating factor (GCSF) for 
the treatment of neutropenia appeared to protect against de novo AIH in one cohort, whereas 
the use of anti-lymphocyte antibodies was associated with a higher risk of de novo AIH in 
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another cohort (64). Recipients treated with tacrolimus or MMF have also had a high risk of 
developing de novo AIH, whereas recipients treated with cyclosporine have had a reduced 
risk (12). These observations suggest that the immune mechanisms contributing to the 
development of de novo AIH are variably affected by regimens of immunosuppression that 
may differ by dose or combination with corticosteroids. This speculation is supported by the 
observation that recurrent PBC (rPBC) is less frequent in recipients receiving cyclosporine 
(6). 
Outcomes and Treatment of De Novo AIH  
De novo AIH can be an aggressive disease in children. In one pediatric cohort, 
progression to advanced fibrosis occurred in 80% of recipients, and graft loss occurred in 
33% despite treatment with corticosteroids and azathioprine (60). Adult patients who develop 
de novo AIH after interferon treatment for recurrent HCV infection may also have an 
aggressive form of the disease. In one series, two of nine patients died, one had graft failure, 
and one required re-transplantation despite the rapid institution of corticosteroid treatment 
(64). 
In one large series of patients with de novo AIH, 38 patients received regimens that 
included azathioprine, 6-mercaptopurine, prednisone, methyl prednisolone, MMF or a 
calcineurin inhibitor. The agents were administered alone or in various combinations, and 
appropriate response and acceptable outcomes were observed in only 40% of patients. Of the 
remaining patients, 10 died, three underwent re-LT, and 10 developed cirrhosis (74).  
Prednisone or prednisolone remains the main treatment of de novo AIH, but combined 
therapy with other immunosuppressive agents has also been used. In adults, prednisone or 
prednisolone, 30 mg daily, in conjunction with azathioprine, 1 to 2 mg/kg daily, is 
recommended (56). In children, prednisone or prednisolone, 1-2 mg/kg (without surpassing 
60 mg daily), in combination with azathioprine, 1-2 mg/kg, is recommended (56). The dose 
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of prednisone or prednisolone should be decreased during a period of 4 to 8 weeks to 
maintain a dose of 5-10 mg daily (56). The importance of prednisone (or prednisolone) and 
low dose maintenance therapy is supported by one study demonstrating that progression to 
cirrhosis, need of LT, or death occurred only in those patients who had not received such 
treatment (31).  
 
Current and Future Strategies to Improve the Management of rAIH and De Novo AIH 
It is important to emphasize that the evidence for the treatment regimens that have 
been used in rAIH and de novo AIH are derived from old studies and are based on small, 
single-center experiences using mainly standard regimens for the treatment of classical AIH. 
MMF has been proposed as a safe and effective first-line therapy in treatment-naive patients 
with classical AIH (75), and MMF may emerge as a substitute for azathioprine after LT. 
Prospective multi-centric studies for the validation and improvement of diagnostic 
and management strategies are necessary to improve graft and patient outcomes after LT. 
In this regard, an important step will be to standardized criteria among the LT centers (Table 
2). 
The effect of induction and maintenance immunosuppressive treatment after LT on 
the incidence and outcomes of rAIH and de novo AIH post-LT should be assessed in a 
standardized manner. Future studies should also include newer immunosuppressive agents 
and combinations. Due to the small number of patients with rAIH and de novo AIH, this can 
only be achieved in a multicentric framework and with a standardized approach regarding 
diagnostic and treatment. Disease-specific biomarkers and a better understanding of the 
immunological pathomechanisms will further improve the diagnosis and management of 
these challenging disorders. 
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CONCLUSIONS 
Liver transplantation for decompensated AIH is associated with 1- and 5-year 
survivals of approximately 90% and 70%, respectively. Recurrent disease has been reported 
to occur in 10-50% of recipients, and the early detection of rAIH by the use of protocol liver 
biopsies might improve detection, strengthen estimates of frequency, facilitate early 
intervention, and improve outcomes. 
Recurrent disease can negatively influence graft and patient survival, and randomized 
controlled trials are warranted to assess predisposing factors and management strategies. The 
administration of low dose maintenance corticosteroids has been reported to minimize the 
occurrence of rAIH (23), and better control of disease activity prior to LT may lower the risk 
of rAIH (5). These strategies should be evaluated in multi-centered collaborative studies. 
De novo AIH can develop in children and adults after LT for liver diseases other than 
AIH, and it may also result in graft failure and the need for repeat LT.  Its place within the 
spectrum of allograft dysfunction is still uncertain, and further studies are needed to 
standardized its diagnosis and distinguish it from plasma cell-rich rejection.  Disease-specific 
serological markers should be sought, and the value of testing for anti-GSTT1 determined. 
Early diagnosis and prompt institution of therapy with prednisone or prednisolone in 
combination with azathioprine are mainstay management principles for rAIH and de novo 
AIH. 
 
Authorship Statement:  
- Guarantor of the article:  Aldo J. Montano-Loza, MD, PhD.  
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
 
 
 
This article is protected by copyright. All rights reserved. 
- Specific author contributions:  
Guido Stirnimann, search and selection of abstracts, review of full-length articles selected, 
and writing final version of manuscript. 
Maryam Ebadi, search and selection of abstracts, review of full-length articles selected, 
writing final version of manuscript; and submitting manuscript for review. 
Albert J. Czaja, search and selection of abstracts, review of full-length articles selected, and 
writing final version of manuscript. 
Aldo J. Montano-Loza, search and selection of abstracts, review of full-length articles 
selected, creation of the first draft of the manuscript, and writing final version of manuscript. 
 
- All authors approved the final version of the manuscript. 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le   
 
This article is protected by copyright. All rights reserved. 
TABLES 
Table 1: Studies Presenting Survival and Frequency of Autoimmune Hepatitis Recurrence After Liver Transplantation 
Author/ 
Year/ 
Country  
n Follow-up 
(Post-LT) 
Frequency 
of rAIH 
n (%) 
Time to 
development 
of rAIH 
Probability 
of rAIH 
(%) 
Post-LT 
biopsy 
procedure 
Immunosuppression  
regimens 
Overall 
Survival/Graft 
Survival 
Prados, et 
al.(40)   
(1998) 
Spain  
 
27 
 
3.7±2.3years 
(range: 8 
months to 9 
years) 
 
Longer follow-
up in patients 
with recurrence 
than in patients 
without 
(5.1±1.9 vs. 
2.5±1.6 years; 
P=0.001) 
9 (33) 2.6 ± 1.5 years 
 
 
8% at 1-year 
68% at 5-
years 
 
Protocol 
biopsies  
(in most 
centres) 
 rAIH 
Single therapy, n=3 
(Cyclosporine or 
Tacrolimus) 
Double, n=6 (Cyclosporine 
+ Prednisone)* 
 
 No rAIH 
Single, n=3 (Cyclosporine 
or Tacrolimus) 
Double, n=8* 
(Cyclosporine + Prednisone) 
Triple, n=7 
(Cyclosporine or 
Tacrolimus + Prednisone + 
Azathioprine) 
 
Mean post-
recurrence follow-
up of 2.4±1 years 
 
No difference in 
patient and graft 
survival rates 
post-LT between 
patients with and 
without 
recurrence 
 
 
Milkiewicz, 
et al. (52) 
(1999) 
UK 
47 Median follow-
up of 50 months 
 
 
13 (28) 29 months 
(range, 6–63) 
NA Protocol 
biopsies 
Not available Graft Loss in 
patients with 
recurrence (n=3) 
Reich et 
al.(42) 
(2000) 
USA 
32 (24 
chronic 
AIH, 8 
(sub)-
fulmina
nt AIH) 
27±14 months 6 out of 
24 (25) 
15±2 months 
(range, 12-18) 
NA Clinically 
indicated 
 rAIH 
Double, n=3 
(Tacrolimus+ Prednisone) 
Triple, n=3 
(Tacrolimus+ Prednisone+ 
Cyclophosphamide) 
 
 No rAIH 
Mean post-
recurrence follow-
up of 23±16 
months (range, 2 
days to 52 
months) 
 
81% survival rate 
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Not available 
 
 
at 1 and 2 years 
post-LT 
 
Graft loss (n=3), 
and death (n=8) in 
patients with 
recurrence 
Gonzalez-
Koch, et al. 
(27) 
(2001) 
USA 
41 Follow-up 
Time tended to 
be longer in the 
patients 
with recurrent 
disease 
(9.5±1.6 vs. 
6.3±0.7 years; 
P=0.07) 
7 (17) 
 
4.6±1 years 
(range, 1.2 to 
7.9 years) 
NA Protocol 
biopsies 
 rAIH 
Single 
Tacrolimus or Cyclosporine, 
n=3 
 
Triple 
Tacrolimus +  Prednisone + 
Azathioprine, n=1 
Cyclosporine + Prednisone 
+ Azathioprine, n=3 
 
Prednisone withdrawal, n=1 
 
 No rAIH 
Single 
Tacrolimus or Cyclosporine, 
n=4 
 
Triple 
Tacrolimus + Prednisone + 
Azathioprine, n=10 
Cyclosporine + Prednisone 
+ Azathioprine, n=20 
 
Prednisone withdrawal, n=1 
No difference in 
5-year patient 
(86% vs. 82%; 
P=0.9) and graft 
(86% vs. 67%; 
P=0.5) survival  
between patients 
with and without 
recurrence 
 
Graft Loss (n=1) 
in patients with 
recurrence 
Duclos-
Valle, et al. 
(43) 
(2003) 
France 
17 Followed for 
more than 10 
years 
 
7 (41) 2.5±1.7 years 
(range, 0.6–
3.0) 
NA Protocol 
biopsies 
(n=4) 
Abnormal 
LFT (n=3) 
 rAIH 
Double 
Cyclosporine +Prednisone, 
n=1 
 
NA 
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Triple 
Cyclosporine + Prednisone+ 
Azathioprine, n=6 
Montano-
Loza, et 
al.(5)  
(2009) 
Canada  
46 79±10 months 
(range, 
6-287 months; 
median, 51 
months) 
11 (24) 
 
48±16 months 
(range, 9-144 
months; 
median, 30 
months) 
18% at 5 
years 
32% at 10 
years 
Clinically 
indicated 
 
 rAIH 
Tacrolimus, n=7 
Cyclosporine, n=4 
Prednisone after LT, n=10 
Long-term prednisone, n=6 
Mycophenolate mofetil, n=9 
Sirolimus, n=2 
 
 
 No rAIH 
Tacrolimus, n=23 
Cyclosporine, n=12 
Prednisone after LT, n=29 
Long-term prednisone, n=14 
Mycophenolate mofetil, 
n=25 
Sirolimus, n=8 
 
Graft dysfunction 
after LT was 
3.6 cases per 100 
patient years 
 
The 5-year 
probability of 
survival in 
patients with and 
without 
recurrence was 
82% and 76%. 
 
Krishnamoor
thy, et al. 
(23) (2016) 
UK 
73 Median follow-
up of 94 months 
(interquartile 
range, 55-144) 
5 (7) 47± 29 months 
 
0%, 4%, 
6%, and 
11% at 1, 3, 
5, and 10 
years 
Protocol 
biopsies in 
50% (until 
2006) 
 rAIH 
Triple 
Tacrolimus + Prednisolone 
+ Mycophenolate mofetil, 
n=2 
Tacrolimus + Prednisolone 
+ Azathioprine, n=3 
 
 No rAIH  
Single  
Tacrolimus, n=2 
Prednisolone, n=1 
   
Double 
Tacrolimus + prednisolone, 
n=12  
Overall survival 
was 92%, 
90%, 86%, and 
73%, and regraft-
free survival was 
86%, 81%, 78%, 
and 64% at 1, 3, 
5, and 10 years, 
respectively 
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Tacrolimus + 
Mycophenolate mofetil, n=4 
Tacrolimus + azathioprine, 
n=3 
Cyclosporine + 
Prednisolone, n=2  
Tacrolimus + 
Hydrocortisone, n=1 
 
Triple 
Tacrolimus + Prednisolone 
+ Mycophenolate mofetil, 
n=23 
Tacrolimus + Prednisolone 
+ Azathioprine, n=13 
Tacrolimus + Prednisolone 
+ Sirolimus, n=3 
 
Excluded: 4 patients (died 
within 3 months) 
rAIH= recurrent autoimmune hepatitis; HLA= human leukocyte antigen; NA=not available; LT=liver transplantation; LFT=liver function tests; * data not 
available for all patients  
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Table 2: Diagnostic Criteria for Recurrence and De Novo Autoimmune Hepatitis 
Disease Diagnostic criteria  
Recurrent 
autoimmune 
hepatitis  
Clinical criteria  
- History of liver transplantation related to AIH   
Serologic findings 
- Hypergammaglobulinemia, increased serum IgG levels, and ANA, 
SMA, or both ANA and SMA (5, 23) 
Histological aspects* 
- Prominent lymphocytic interface activity with or without plasma cell 
infiltration (37, 46) 
- Acute lobular hepatitis with focal hepatocyte necrosis, acidophil 
bodies with lymphoplasmacytic cells (37, 46) 
- Pseudo-rosetting of hepatocytes, and perivenular lymphoplasmacytic 
inflammation (37) 
- Confluent and bridging necrosis with lymphoplasmacytic infiltration 
(severe inflammatory activity) 
* Features may be less pronounced, absent, or otherwise atypical in part because of 
concurrent antirejection therapy (43-45). 
De novo 
Autoimmune 
hepatitis  
Clinical criteria  
- History of liver transplantation not related to AIH   
Serologic findings 
- Hypergammaglobulinemia, increased serum IgG levels, and ANA, 
SMA, or both ANA and SMA (12) 
- Atypical anti-liver/kidney cytosolic antibody targeting the antigen 
glutathione-S-transferase T1 (GSTT1) (31, 71) 
- Children with de novo AIH may have anti-LKM1, antibodies to 
gastric parietal cells, or anti-LC (68) 
Histological aspects 
- Portal and periportal (interface) hepatitis with lymphocytes and 
plasma cells (11) 
- Perivenular cell necrosis (11), lobular hepatitis (31), portal fibrosis 
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(60, 68), zonal necrosis (61), and centrilobular necrosis (62) 
Recurrent and 
De novo 
Autoimmune 
hepatitis 
Exclusion of alternative etiologies 
- T-cell mediated rejection: focal lymphocytic cholangitis and 
perivenular hepatocyte necrosis of the terminal hepatic venules 
support this diagnosis (37) 
- drug hepatotoxicity, de novo steatohepatitis, viral hepatitis, including 
hepatitis E 
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Table 3: Risk Factors for Recurrence and De Novo Autoimmune Hepatitis  
Disease Risk Factors for Recurrence  Statistical method applied 
Recurrent 
autoimmune 
hepatitis  
 Discontinuation of steroid therapy (52) Observational Study* 
 HLA-miss matching between donor and recipient 
for HLA-DR3 or DR4 (43, 53, 76) 
Observational Study (43, 76) 
Multivariate Cox analysis (53)  
  Tacrolimus based Immunosuppressive regimens 
(46) 
Univariate analysis (Fisher’s 
exact test) 
  HLA-DR3 or HLA-DR4 incidence in the 
transplant recipient (27) 
Univariate analysis (Fisher’s 
exact test) 
  Abnormal pre-LT AST, ALT, IgG (5) Multivariate Cox analysis  
  Re-transplantation for recurrent AIH (42) Observational Study 
  Transplantation for chronic AIH (patients 
transplanted for fulminant AIH seem to be 
protected from recurrence) (42) 
Observational Study 
  Concomitant autoimmune disease (5) Multivariate Cox analysis 
  Moderate to severe inflammatory activity or 
plasma cell penetration in the liver explants (5)  
Multivariate Cox analysis 
  High-grade inflammation in the native liver at LT 
(46) 
Univariate analysis (Fisher’s 
exact test) 
De novo 
Autoimmune 
hepatitis  
 Anti-lymphocyte antibodies use (64) Univariate analysis (Fisher’s 
exact test) 
 Antiviral therapy for HCV infection with 
pegylated interferon and ribavirin (64) 
Observational Study 
  Female grafts or older donors recipients (12) Multivariate Cox analysis 
  Atypical serum autoantibodies such as GSTT1 
donor/recipient genotype mismatch (72, 73) 
Univariate analysis (Fisher’s 
exact test) (72) 
Multivariate Cox analysis (73) 
  Tacrolimus, or mycophenolate mofetil use as part 
of immunosuppressive therapy (12) 
Multivariate Cox analysis 
  Number of episodes of rejection (77) Univariate analysis (Student’s t- 
test) 
  Acute rejection episode (78) Multivariate Cox analysis 
   Nonalcoholic etiology (73) Multivariate Cox analysis 
AIH= autoimmune hepatitis; ALT=; alanine aminotransferase; AST= Aspartate transaminase;  
GSTT1= glutathione S-transferase T1; HLA= human leukocyte antigen; IgG= immunoglobulin G; 
LT=liver transplantation;  
*Observational Study: No statistical analysis was conducted 
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Table 4: Studies Presenting Frequency of De Novo Autoimmune Hepatitis 
Author/ 
Year/ 
Country  
n Follow-up 
(Post-LT) 
Frequency of 
Recurrence 
n (%) 
Time to 
development of 
Recurrence 
Overall 
Survival/Graft 
Survival 
 
Pediatric Population  
 
Kerkar, et al.(11) 
(1998) 
UK 
180 NA 7(4) 23±15 months 
(6-45) 
Graft Loss (n=7) 
Gupta, et al.(60) 
(2001) 
USA 
115  6 (5) 8.5 years (range 
5–13) 
Graft Loss (n=1) 
Spada, et al. (79) 
(2001) 
Italy 
116 NA 5 (4) 29 months (range 
17 to 111) 
Graft Loss (n=1) 
Venick, et al.(77) 
(2007) 
USA 
619 NA 41(7) 7.0±1.2 years Mean follow-up of 
4 years 
Graft Loss (n=3) 
Death (n=2) 
Cho, et al.(69) 
(2011) 
Korea 
149 NA 4 (3) Median of 6.5 
years (range, 
0.7–8.8 years) 
NA 
Ekong, et al. (80) 
(2017) 
USA/ 
Canada/ 
UK 
1833 NA 31 (2) Median 5.3 years 
(range 1.2-14.9) 
 
Median follow-up 
of 7.1 years (1.6-
15) 
Graft loss (n=2) 
Death (n=1) 
 
 
 
Pediatric and Adult Population  
 
Miyagawa-
Hayashino, et al. 
(78) (2004) 
Japan 
633 6.1 (4.3– 
10.4) years 
13 (2) 3.6±2.6 years Patients were 
followed for a 
median of 3.5 (0.1– 
8) years  
 
Graft Loss (n=3) 
Montano-Loza, 
et al.(12)  
(2012) 
Canada 
576  17 (3) 84±16 months 
(range 3–201) 
Similar survival in 
patients who 
developed de novo 
AIH compared to 
the rest of LT 
recipients 
 
The 5-year 
probability of 
survival  
was 100 and 84% 
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in patients with and 
without 
de novo AIH  
 
Adult Population  
 
Eguchi, et al.(81) 
(2008) 
Japan 
72 Median 
follow up of 
42.5 months 
(range 26–
57 months) 
4 (6) 19±19 months 
(range 3-41) 
 
NA 
Salcedo, et al. 
(73) (2009) 
Spain 
419 Median 
follow up of 
90.85 
months 
(95% CI, 
40.71-
141.00) 
20 (5) Median 
follow-up of 26 
months (95% CI, 
19.2-32.8) 
Graft loss (n=6) 
 
HLA= human leukocyte antigen; NA=not available.   
 
 
 
FIGURE LEGEND 
Figure 1. Main pathogenic mechanisms implicated in the development of recurrent 
and de novo autoimmune hepatitis. In recurrent autoimmune hepatitis (upper row), 
antigen presenting cells (APC) of the recipient re-populate the donor liver, present self-
antigens, and sensitize naïve CD4
+
 T lymphocytes to the antigens (panel a). Self-
tolerance is overridden by molecular mimicry and the targeting of homologous antigens 
by activated cytotoxic T lymphocytes (CTL). The mimicries may involve cytochrome 
P450 2D6 (CYP2D6,), transfer ribonucleic acid (tRNA); transfer ribonucleoprotein 
involved in serine (ser) and selenocysteine (sec) metabolism (tRNA(SER)SEC), and 
formiminotransferase cyclodeaminase (FTCD) (panel b). Activated CD4
+
 T cells 
differentiate along cytokine pathways to activated CTL (type 1 cytokine pathway) and to 
B cells and plasma cells (type 2 cytokine pathway) (panel c). Antibody-producing plasma 
cells and activated CTL initiate an apoptotic pathway mediated by the first apoptosis 
signal receptor (Fas) and Fas ligand (FasL), and natural killer T (NKT) cells interact with 
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Fc receptors (FcR) to initiate cell-mediated cytotoxicity. The consequence of these 
interactions is an anti-graft response (panel d). 
In de novo autoimmune hepatitis (second row), the APCs of the recipient re-populate the 
donor liver and present self-antigens (panel a). The donor CD4+ T helper cells are primed 
by mimics of alloantigens, glutathione-S-transferase T1 (GSTT1), antigens of the major 
histocompatibility complex (MHC), or viral antigens (panel b). Activated CD4+ T cells 
differentiate along cytokine pathways into plasma cells and activated CTL (panel c). 
Antibody-producing plasma cells, activated CTL, and NKT cells induce an anti-graft 
response (panel d). 
*NKT cell CD94 (NKG2D) receptors bind to HLA class I MICA and MICB ligands and 
to non-HLA ULPB stress proteins expressed on target cells. 
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